Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Endocrinology

Synergistic Cytotoxicity Exhibited by Combination Treatment of Selective Retinoid Ligands with Taxol (Paclitaxel)

Valerie Vivat-Hannah, Dan You, Cheryl Rizzo, Jean-Paul Daris, Philippe Lapointe, F. Christopher Zusi, Anne Marinier, Matthew V. Lorenzi and Marco M. Gottardis
Valerie Vivat-Hannah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan You
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Rizzo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Paul Daris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Lapointe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Christopher Zusi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Marinier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew V. Lorenzi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco M. Gottardis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published December 2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The focus of this study was to develop retinoic acid receptor (RAR) RARα/β selective agonists with anticancer efficacy and reduced toxicity associated with RARγ activity. In these studies, we report the identification and characterization of high-affinity RARα/β selective agonists with limited RARγ activity. These compounds inhibited human tumor cell line proliferation with similar efficacy to that observed for a pan-RAR agonist. However, for most tumor cell lines, the efficacy of these compounds was restricted to the micromolar range. To determine whether the RARα/β selective agonists could be additive or synergistic with existing agents, we investigated the effects of combining RARα/β selective agonists with various cytotoxic agents. Our results showed that the α/β selective retinoids dramatically lowered the effective dose of Taxol needed to induce cytotoxicity of a wide range of tumor cell lines. This synergy was specific to tubulin-modifying agents and could not be observed with a variety of other cytotoxic agents of diverse function. Examination of pathways common to Taxol and retinoid signaling revealed that this synergy was related in part to effects on Bcl-2 expression/phosphorylation as well as the activity of the c-Jun NH2-terminal kinase and activator protein-1. In contrast, the tubulin polymerization induced by Taxol was not further affected by cotreatment with a variety of retinoid receptor ligands. These observations indicate that potent RARα/β selective agonists may be of therapeutic benefit in combination with Taxol therapy.

INTRODUCTION

The retinoids are biologically active derivatives of vitamin A that can regulate the proliferation, differentiation, and apoptosis of a wide variety of both normal and malignant cells (1, 2, 3) . The natural retinoids primarily consist of ATRA2 and 9-cis retinoic acid, which are processed from vitamin A through its irreversible oxidation (4 , 5) . In addition, several synthetic ligands have been designed that retain many of the biological properties of the natural ligands (6 , 7) . The biological activities of the retinoids are mediated by two classes of nuclear receptors, the RARs and the RXRs, each of which comprise three isotypes designated α, β, and γ (reviewed in Ref. 8 ). RAR and RXR act as ligand-dependent transcription factors, which can modulate target gene expression by binding as RAR/RXR heterodimeric complexes to a specific RAR element DNA sequence (9 , 10) . The activity of the RAR/RXR heterodimer can be repressive or stimulatory, depending upon its apo (unliganded) or holo (ligand-bound) conformation, respectively. The apo conformation of RAR/RXR heterodimers allows protein interactions with large corepressor multiprotein complexes that contain nuclear corepressor and histone deacetylases and act to maintain the chromatin in a condensed transcriptionally inactive state to repress target gene expression (11, 12, 13) . In contrast, the binding of agonist ligand to RARs is associated with a conformational transition of the ligand binding domain (14) , resulting in the destabilization of the corepressor complex and simultaneous recruitment of coactivators, including p160 protein family, CBP/p300, and the multiprotein complexes thyroid hormone receptor associated proteins (TRAP), Vitamin D3 receptor interacting proteins (DRIP), activator recruited cofactor (ARC) (11) . Some of these factors contain histone acetyltransferase activity, allowing the decondensation of the chromatin required for the subsequent link of the holo-RAR/RXR heterodimer with the basal transcriptional complex to initiate target gene expression (11 , 13) .

ATRA and synthetic retinoid receptor ligands have been shown to promote tumor regression in a number of animal models of carcinogenesis and have shown efficacy in patients afflicted with acute promyelocytic leukemia (15 , 16) . Among the three RAR isotypes, the RARβ2 isoform has been associated with the tumor-suppressive effects of the retinoids. RARβ2 arises from alternative promoter use of the RARβ gene promoter P2 (8) , which contains a strong RAR element, suggesting that RARβ expression is up-regulated by retinoic acid and places RARβ2 as a potential target gene underlying the growth-suppressive effects of retinoic acid. Furthermore, a large number of reports have described the loss of the RARβ2 expression during the early phases of cancer development including breast and lung tumors (17, 18, 19) . In contrast, the expression of RARα and RARγ as well as RXRα are mostly unaltered in malignant tissues. Consistent with a role in modulating cell growth, RARβ gene inactivation in several cell types has led to the loss of retinoic acid-dependent growth arrest (20 , 21) . In contrast, the induction of RARβ expression in different tumor cell lines has been shown to be associated with a strong enhancement of retinoic acid responsiveness (22 , 23) . These observations highlight RARβ as an important mediator of retinoid action and suggest that its modulation may be effective in reducing tumor cell growth.

A growing interest has focused recently on increasing the antitumor activity of the retinoids through combination with other types of agents, including IFN-α (24) , tumor necrosis factor-related apoptosis-inducing ligand (25) , HDAC inhibitors (26, 27, 28) , as well as chemotherapeutic agents (29, 30, 31, 32) . For instance, in cell lines isolated from patients afflicted with acute myeloid leukemia, HDAC inhibitors potentiate the differentiation effects of the retinoids and show activity in retinoid-resistant acute myeloid leukemia cells (26) . The molecular mechanisms underlying the effect of these agents are related to the derepression of the retinoid receptor transduction pathway (26) . For instance, in breast cancer cells, HDAC inhibitors have been shown to restore the retinoic acid-inducible expression of RARβ, independently of the methylation status of the RARβ gene promoter (33) . In contrast, the mechanisms supporting the synergistic effects observed in combination treatments using the retinoids and IFN-α, or with chemotherapeutic agents such as cisplatin or Taxol, remain largely undefined.

In the present study, we report the identification of selective RARα/β agonists and the effects of these ligands at inhibiting tumor cell proliferation. The engineered RARα/β agonists were generally found to be weak inducers of cytotoxicity in a variety of tumor cell lines as single agents. However, when administered with Taxol, RARα/β agonists dramatically lowered the inhibitory concentration of the tubulin-polymerizing agent to induce a cytotoxic response. The ability of RARα/β selective ligands to synergize with Taxol was correlated with effects on the antiapoptotic protein Bcl-2 and with the activities of JNK and AP-1, pathways common to both retinoid and Taxol signaling. These observations indicate common retinoid-Taxol signaling pathways mediating cell proliferation and suggest that RARα/β agonists may have potential for use in combination regimens with Taxol.

MATERIALS AND METHODS

Materials.

The cell lines used in this study including T47D, HT-3, UMSCC-25, MCF7, OVCAR3, HCT-116, and N-87 were obtained from American Type Culture Collection and maintained in the media and serum concentration recommended by American Type Culture Collection. The H3396 cell line was obtained from Dr. K. E. Hellstrom (Bristol-Myers Squibb, Seattle, WA; Ref. 34 ), and maintained in RPMI supplemented with 10% FBS (Life Technologies, Inc.). MDA-PCA.2B and SQCC-Y1 were obtained from Drs. N. Navone and S. M. Lippman (M. D. Anderson Cancer Center, Houston, TX), respectively. A2780S and its p27 transgenic variant A2780p27, HCT-116TXPK (Taxol-resistant) and HCTVM46, SAN-1, M109 and its Taxol-resistant variant M109TX, and PAT-7 (Taxol resistant) cell lines3 engineered for drug resistance were also used. All cell lines were of human origin except SAN-1, M109, and its variant M109TX, which were murine cell lines. All of the cytotoxic agents, with the exception of Taxol, and PMA were purchased from Sigma Chemical Co.-Aldrich. The mouse anti-αBcl-2, anti-α-tubulin, and anti-human JNK antibodies used in this study were purchased from Biosource International, Sigma Chemical Co.-Aldrich, and BD-PharMingen, respectively. The c-jun (1–169)-GST fusion protein was obtained from Upstate Biotechnology.

Synthetic RAR Ligands.

A detailed description of the routes of syntheses and structures of chemical intermediates used to generate BMS-228987, BMS-276393, BMS-231974, BMS-209641, BMS-270394, and BMS-313493 are available upon request. The RAR and RXR ligands, BMS-194753 and BMS-188649 (SR-11237), respectively, have been described previously (35 , 36) . The selectivity of all retinoids used in this study was determined on HeLa stable cell lines expressing Gal-RARα, Gal-RARβ, or Gal-RARγ along with the (17-mer)5x-Glob-Luc reporter gene (37) .

Mitogenic Assay.

Cellular proliferation was quantified using [3H]thymidine incorporation. Briefly, the cells were plated in 96-well plates in medium containing 10% FBS. Cell medium was removed the following day, and the indicated compounds were added to fresh medium supplemented with 10% of charcoal-stripped FBS (HyClone). Compound-containing medium was renewed after 3 days exposure. After 6 days of treatment, 4 μCi/ml of [3H]thymidine (NEN Life Science Products) were added to each well for 2–4 h. The cells were then trypsinized and harvested on GF/B glass fiber filters. [3H]Thymidine incorporated into the DNA was measured in a scintillation Topcount counter (Packard). The results were expressed as a percentage of inhibition compared with the DMSO vehicle. IC50 was defined as the concentration of compound inducing 50% inhibition, and the efficacy corresponded to the maximal inhibition obtained in response to the compound and compared with DMSO. The results are the means of two to five independent experiments with duplicate measurements.

Anchorage-dependent Colony Formation Assay.

To determine effects of RAR agonists on anchorage-dependent colony size, number, and morphology, MCF7 cells were plated in six-well plates (500 cells/well) in DMEM supplemented with 10% FBS and grown for 5 days. The medium was then removed, and the compounds were added to the medium supplemented with 5% of charcoal-stripped FBS (HyClone). The compound containing medium was renewed after 3 days, and cultures were allowed to grow an additional 3 days. After 6 days exposure to compounds, colonies were stained with crystal violet and photographed under light microscopy to assess effects on colony size and morphology. In parallel, the number of colonies was counted using an Optomax/Sorcerer colony counter and image analyzer.

Immunoblotting.

MCF7 cellular lysates were prepared for Western blotting as described (38) . Briefly, cell lysates were prepared by adding 200 μl of lysis buffer [Tris-HCl (pH 6.8), 20 mm, EDTA 1 mm, and 0.5% NP40] containing a protease inhibitor mixture (Roche) to each well of six-well plates. The lysates were then cleared by centrifugation at 10,000 rpm, 4°C for 5 min, and supernatants were adjusted with Laemmli sample buffer and processed by 10 or 15% SDS-PAGE, followed by transfer to nitrocellulose membranes (Bio-Rad). Membranes were processed by standard methods and incubated with primary antibodies for 1 h at room temperature or overnight at 4°C. Bound antibody was visualized using a goat anti-IgG secondary antibody conjugated to horseradish peroxidase and a chemiluminescent detection system (ECL; Amersham Pharmacia Biotech).

Tubulin Polymerization Assay.

The effects of retinoid and Taxol exposure on free and polymerized tubulin levels were determined as described previously (39) . Briefly, MCF7 cells were plated in six-well plates in DMEM supplemented with 10% FBS and allowed to adhere overnight. Cell medium was removed the next day, and the indicated compounds were added to fresh medium supplemented with 5% charcoal-stripped FBS (HyClone). The cells were grown for 3 days in the presence of the retinoids before Taxol was added for 1 h. Soluble and polymerized tubulin were extracted, and respective levels were assessed by Western blotting as described above using anti-α-tubulin antibodies at 1:1000 (n = 2).

AP1 Reporter Assay.

AP1 transcriptional activity was assessed in MCF7 cells stably expressing the (AP1)5x-tk-Luc reporter gene (37) . The reporter construct consists of the collagenase gene AP1 response element repeated five times in tandem [(AP1)5x], the minimal tk promoter, and the coding sequence of the luciferase gene (Luc). For AP1 activity measurements, MCF7 cells were plated in 12-well plates at a density of 400,000 cells/well in DMEM supplemented with 10% FBS and allowed to adhere overnight. The next day, the medium was removed; the cells were washed with PBS and supplemented with DMEM medium containing 0.5% of charcoal-stripped FBS (HyClone). Twenty-four h later, the cells were treated for 6 h with PMA (10 nm) in the absence or the presence of ATRA, BMS-231974, or BMS-228987 (concentrations ranging from 0.1, 1, and 50 nm) combined with or without Taxol (1 μm). The luciferase activity was measured by using Luc-lite system from Packard according to manufacturer’s recommendations. Results are expressed as the percentage of activity compared with PMA (10 nm), which was assigned as 100% activity. The data presented are the mean ± SE of three independent experiments.

JNK Assay.

Activity of JNK was measured as described (40) with minor modifications. Briefly, MCF7 cells were plated in six-well plates in DMEM supplemented with 10% FBS. The next day, the cells were switched to DMEM supplemented with 0.5% charcoal-stripped FBS (HyClone), and 100 nm indicated retinoids or 0.1% DMSO was added to the cells for 24 h before an additional 2–3 h incubation in the presence of Taxol. JNK was immunoprecipitated from cleared cellular lysates by incubating overnight at 4°C with 1 μg of anti-human JNK (PharMingen) and 25 μl of protein G-agarose beads (Life Technologies, Inc.) washed previously with the lysis buffer. Immune complexes were pelleted by centrifugation and processed as described for JNK activity using 2 μg of GST-c-Jun (1–169) fusion protein. Samples were resolved by 10% SDS-PAGE, and phosphorylated GST-c-Jun was visualized by autoradiography and quantified by densitometry. The results represent the mean ± SE of three independent experiments.

RESULTS

RARα/β Selective Agonists Display Efficacy at Inhibiting Tumor Cell Proliferation.

Although RARβ has been described as a key player of retinoid-induced growth inhibition, this isotype is most often lost during the process of carcinogenesis, and thus, the use of a pure RARβ agonist (BMS-209641) is inactive at inhibiting tumor cell proliferation (unpublished data).3 Taking into account the undesirable RARγ-related toxicity (41 , 42) and the possibility that RARβ might be induced by retinoid treatment (43) , the compounds chosen for this study exhibited both α- and β-agonistic selectivities without significant RARγ activity. The structures of the compounds and their selectivity profile for retinoid receptors are presented in Fig. 1⇓ .

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Structure and selectivity of the retinoid derivatives. A, chemical structure of the synthetic retinoids (left diagram) compared with ATRA (right diagram). B, transcriptional activity of ATRA and the synthetic retinoids. ATRA is a pan-agonist for RAR. All synthetic retinoids are RAR specific and do not display binding to RXR. BMS-231974 is a pan-RAR agonist with β > α > γ selectivity. BMS-228987 and BMS-276393 are α/β selective agonists with β ≥ α selectivity. Weak residual γ activity could be detected (∼25% at 3 μm ligand) for BMS-228987 and BMS-276393. BMS-209641 is a pure RARβ agonist, and BMS-270394 is a γ-selective agonist with low β-agonist activity. BMS-313493 is a pan-RAR antagonist. The data are the means of three independent experiments, where each ligand was tested in duplicate. The SDs associated with EC50s/IC50s were between 10 and 15%. −, no effect was observed.

Because ATRA and synthetic retinoids have displayed the ability to arrest the growth of cancer cells, the selective RARα/β agonists, BMS-228987 and BMS-276393, were first compared with the natural and synthetic RAR pan-agonists, ATRA and BMS-231974, respectively. The proliferation of 6 of 18 tumor cell lines (e.g., T47D, H3396, HT3, SAN1, SCC25, and MCF7) was inhibited by nanomolar concentrations of α/β selective retinoids (Table 1)⇓ . The maximum effect on growth inhibition ranged from 55 to 100%, as compared with DMSO. The remaining tumor cell lines were less sensitive to the antiproliferative effect of these retinoid ligands with IC50s restricted to the high micromolar concentration. In most tumor cell lines tested, the α/β selective agonists appeared as efficient as the RAR pan-agonist at inhibiting tumor cell proliferation, suggesting that the γ isotype of RAR is not critically required for the tumor-suppressive activity of the retinoids. In the SQCC-Y1 head and neck squamous carcinoma cell line, the 2 log difference in ATRA IC50s compared with the synthetic retinoids might be attributed to the participation of RXR because ATRA can be converted in situ into 9-cis-RA which is a pan-RAR and RXR agonist. Conversely, the lack of activity of ATRA compared with the synthetic compounds in several cell lines might reflect a difference in the stability of natural versus synthetic retinoid because the rapid metabolism of ATRA in some cell lines has been observed (5 , 20) .

View this table:
  • View inline
  • View popup
Table 1

Inhibition of tumor cell proliferation by retinoids

The ability of MCF7 cells to form colonies was assayed in the presence of the selective RARα/β agonist, BMS-228987, and compared with ATRA. The colonies grown in the presence of BMS-228987 revealed a strong differentiating effect of the retinoid that is similar to that observed with ATRA. In contrast, vehicle-treated cells formed very compact colonies, with cells showing a very restricted cytoplasm, and most of the colonies appeared very well segregated (Fig. 2a)⇓ . The treatment of MCF7 cells with ATRA (Fig. 2b)⇓ or BMS-228987 (Fig. 2c)⇓ resulted in a dramatic change in the morphology of both the colonies and the cells. The colonies appeared dispersed, the cells gained in volume, exhibited a large cytoplasm, and tended to organize into an epithelium-like structures (Fig. 2b⇓ for ATRA and 2c⇓ for BMS-228987). The number of colonies was only slightly decreased by BMS-228987 treatment (15%; P < 0.05) compared with DMSO-treated colonies (Fig. 2d)⇓ , suggesting that retinoids were inducing differentiation rather than frank apoptosis.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Effects of combination treatments on MCF7 colony formation. ATRA and RARα/β selective agonists induced strong morphological changes to MCF7 colonies. Cells were plated in six-well plates and allowed to grow for 5 days before being treated for 6 days with 0.1% DMSO (a), ATRA (b), or BMS-228987 (c) at 100 nm. At the end of the treatments, colonies were stained with crystal violet dye and counted (d). The data are expressed as the percentage of colony number compared with control treatment (DMSO) and represents the average of two independent experiments, where the compounds were tested in triplicates. The Student t test was used to establish statistical significance. ∗ and ∗∗ correspond to Ps <0.05 and < 0.005 compared with DMSO treatment, respectively, whereas # corresponds to P <0.05 compared with Taxol treatment.

Cytotoxicity of Taxol Is Strengthened by RARα/β Selective Retinoids.

To determine whether the effect of the RARα/β selective agonists on cell growth could be additive or synergistic with existing chemotherapeutic agents, we investigated the combined use of RAR selective ligands with various cytotoxic agents. The colony assays performed with MCF7 cells (Fig. 2d)⇓ showed that Taxol-induced apoptosis resulted in the dose-dependent decrease of the colony number (by 45% at 10 nm Taxol), which was even more dramatically pronounced when Taxol was combined with the α/β selective retinoid, BMS-228987, and resulted in a reduction of 80% of the MCF7 colony number (Fig. 2d)⇓ . Similarly, cotreatment of a variety of cell lines with Taxol and the RARα/β selective agonist, BMS-228987, dramatically lowered the effective dose of Taxol to induce cytotoxicity. In the presence of BMS-228987, the IC50 of Taxol was decreased by 8-, 15- and 32-fold in MCF7, OVCAR3, and SQCC-Y1, respectively. These values were very similar to those obtained for the combination of Taxol with the RAR pan-agonist BMS-231974 (Fig. 3⇓ and Table 2⇓ ), which supports the major role of RARα/β isotypes in the tumor-suppressive activity of the retinoids. In contrast, the pure RARα agonist BMS-194753 was associated with only a 2–4-fold decrease in Taxol IC50s (Table 2)⇓ , which is in agreement with its lower affinity for RARα compared with BMS-228987 (not shown). Interestingly, the pure agonist for RARβ, BMS-209641, the RARγ-selective, BMS-270394, or the pure RXR agonist, BMS-188649, did not affect Taxol cytotoxicity by more than 2–3-fold, suggesting that the synergistic effects of the RARα/β ligands with Taxol is mainly mediated by RARα (Table 2)⇓ .

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Cytotoxic synergy between Taxol and α/β selective retinoid ligands. The combination of Taxol with selective RAR agonists decreases the dose of Taxol required to induce 50% inhibition (IC50) of MCF7, SQCC-Y1, and OVCAR3 cell proliferation as measured by [3H]thymidine incorporation. The effect of the retinoids alone on these cells is presented in Table 1⇓ . The cells were plated in 96-well plates and treated for 6 days with a fixed dose of retinoids (defined as inducing ∼30% inhibition of cell growth) or 0.1% DMSO, and increasing concentrations of Taxol ranged from 1 pm to 100 nm. The medium was changed once, and fresh compounds were added after 3 days. The results are expressed as the percentage of inhibition compared with vehicle and are the means of two to five separate experiments where each compound was tested in duplicates; bars, SE.

View this table:
  • View inline
  • View popup
Table 2

Selectivity required for retinoid/Taxol synergistic inhibition of cell growth

To determine whether the effect of retinoids on lowering the effective dose of Taxol could be extended to other classes of chemotherapeutic agents, a variety of anticancer cytotoxic compounds including other tubulin-modifying agents and DNA-modifying agents were also assayed for their potential to synergize with the retinoids at inhibiting cell proliferation. The mechanisms of action of the different drugs depicted in Table 3⇓ include DNA cross-linking for cisplatin, inhibition of topoisomerases I and II for camptothecin and doxorubicin, respectively, depolymerization of tubulin microfilaments for colchicine and vinblastine, and inhibition of thymidylate synthase for 5-fluorouracil, associated with an incorporation of fluorouracil into cellular RNAs. The sensitivity of MCF7, SQCC-Y1, and OVCAR3 to these cytotoxic agents was unaffected or only weakly reduced in the presence of the pan-RAR agonist BMS-231974 (Table 3)⇓ . Of the agents tested, only the IC50s of vinblastine was decreased in all three cell lines, but to a lesser degree (2.5–5 fold) compared with the synergy observed with Taxol. Taken together, these data demonstrate the synergy between cytotoxic compounds and retinoids was specific to tubulin modifying agents, particularly Taxol, and was dependent mainly upon the activity of the RARα.

View this table:
  • View inline
  • View popup
Table 3

Combination effect of retinoids and chemotherapeutic agents on tumor cell proliferation

Retinoids Do Not Affect Taxol-induced Tubulin Polymerization.

To better understand the molecular basis of the synergistic effect between Taxol and the RARα/β selective retinoids, we analyzed the effects of both compounds on various signal transduction pathways affected by these agents. The combination effect of Taxol and RARα/β agonists was analyzed at the level of tubulin polymerization. The soluble, nonpolymerized tubulin was separated from insoluble polymerized tubulin and analyzed by Western blotting using anti-α-tubulin antibodies. The results shown in Fig. 4⇓ reveal a dose-dependent polymerization of tubulin induced by Taxol (Lanes 1–6), whereas the selective RAR agonists (Fig. 4⇓ , Lanes 7 and 13 versus Lanes 8 and 14) or antagonist (Fig. 4⇓ , Lane 19 versus Lane 20) had no effect. The combination of Taxol with any of the retinoids did not enhance the effect of Taxol alone (Fig. 4⇓ , compare Lanes 3–6 with Lanes 9–12, with Lanes 15–18, and with Lanes 21–24). These observations indicate that the retinoids do not synergize with the effects of Taxol on the cytoskeleton to induce cytotoxicity.

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

Taxol-induced tubulin polymerization is retinoid independent. The combined effects of retinoids and Taxol on the polymerization of tubulin in MCF7. Cells were treated with the indicated compounds, and lysates were prepared for analysis of soluble nonpolymerized tubulin and insoluble polymerized tubulin levels by Western blotting. Lanes 1, 2, 7, 13, and 19 are from untreated or vehicle treated cells. Arrows, the migration of soluble, nonpolymerized tubulin (a) and insoluble, polymerized tubulin (b). The blot shown is representative of two independent experiments.

Cross-Regulation of AP1 Activity by Retinoids and Taxol.

Several recent reports have described Taxol-induced stimulation of JNK activity, leading to an increase in c-Jun phosphorylation and associated increase activity of the AP1 transcription complex (44) . Retinoids have also been shown to regulate AP1 transcriptional activity (37) . To determine whether the observed synergy correlated with effects on the JNK-AP1 axis, we analyzed the combination effect of Taxol and retinoids on JNK kinase activity and AP1 transcriptional activity in MCF7 cells (Fig. 5)⇓ . Analysis of JNK activity revealed that the treatment of MCF7 cells by Taxol resulted in an average of 2.5-fold increase in JNK activity (Fig. 5A)⇓ , whereas the retinoids alone had no effect on JNK activity (not shown). In contrast, the combination of Taxol with ATRA, the pan-RAR agonist, BMS-231974, or the α/β selective agonist, BMS-228987, slightly increased Taxol-induced JNK activity, yielding a maximum 4-fold increase in JNK enzymatic activity. These effects on JNK were further analyzed at the level of the AP1 transcription complex activity by using MCF7 cell line stably expressing the AP1 reporter gene, (AP1)5x-tk-Luc. The basal activity of the reporter construct was not affected either by the retinoids or by Taxol (Fig. 5, B and C)⇓ , suggesting that jun/fos heterodimers are not constitutively binding to the AP1 response elements and that effects of these agents on AP1 require activation of the complex. Accordingly, MCF7 cells treated with PMA, a potent activator of AP1, resulted in a robust AP1 transcriptional activity yielding a 10-fold increase in luciferase activity (Fig. 5B)⇓ . The PMA-induced AP1 activity was inhibited in a dose-dependent manner by various retinoids including ATRA, the pan-RAR agonist (BMS-231974), or the selective RARα/β agonist (BMS-228987) reaching a maximum of 45% at 50 nm compounds (Fig. 6B)⇓ . As expected, Taxol further enhanced AP1 activity by 20% (P < 0.01; Fig. 5C⇓ ). However, in combination with ATRA, BMS-231974, or BMS-228987, the effect of Taxol on AP1 was abrogated in a dose-dependent manner, resulting in a overall inhibition of the collagenase promoter activity by up to 50% (Fig. 5C)⇓ . Taken together, these data show that the combination effect of Taxol and the α/β selective RAR agonists at stimulating JNK activity becomes dissociated from the subsequent increase in AP1 activity.

Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Effects of retinoids and Taxol on the JNK pathway and AP1 activity. A, Taxol-induced JNK activity in MCF7 is amplified by retinoids. MCF7 cells were treated for 24 h with DMSO (0.1%), ATRA (50 nm), BMS-231974 (100 nm), or BMS-228987 (100 nm) before adding 1 μm Taxol for an additional 2–3 h. JNK activity was measured for each condition after immunoprecipitation with a specific monoclonal anti-JNK antibody. B and C, AP1 transcriptional activity is inhibited by RAR-selective retinoids independently of Taxol treatment. PMA (10 nm), Taxol (1 μm), ATRA, BMS-231974, and BMS-228987 (0.1, 1, and 50 nm) were added for 6 h prior to luciferase activity measurements. The results represent the means of three independent experiments; bars, SE. Statistical analysis used the Student t test. ∗, ∗∗, and ∗∗∗ correspond to Ps of <0.05, <0.01, and <0.001 compared with PMA treatment, respectively. # and ## correspond to Ps of <0.05 and <0.01 compared with the combination PMA and Taxol, respectively.

Fig. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 6.

Dual regulation of Bcl-2 in response to retinoids and Taxol. Combined effects of retinoids and Taxol on Bcl-2 protein expression levels and phosphorylation state was assessed in MCF7 cells by Western blotting analysis. MCF7 cells were treated for 3 days with 0.1% DMSO, 100 nm pan-RAR agonist BMS-231974, the α/β-selective retinoid BMS-228987, or with 1 μm pan-RAR antagonist, BMS-313493. Increasing concentrations of Taxol (1, 10, and 100 nm to 1 μm) were then added for an additional 24 h. Cellular lysates of each condition were analyzed by Western blotting using a monoclonal antibody against human Bcl-2 (1:1000). The blot shown is representative of two independent experiments.

Combination Effects of Taxol and Retinoids on Bcl-2.

We examined next the effects of Taxol/retinoid cotreatment on the expression levels and phosphorylation status of the antiapoptotic protein, bcl-2, a protein implicated in both retinoid and Taxol signaling. MCF7 cells treated with Taxol displayed a dose-dependent increase in the phosphorylation of bcl-2, which is characterized by a higher molecular weight upper band (Fig. 6⇓ , Lanes 1–6). The addition to the cells of RAR pan- or selective α/β agonists resulted in a down-regulation of the Bcl-2 protein levels (Fig. 6⇓ , compare Lanes 7 and 8; Lanes 13 and 14), whereas the RAR-selective antagonist alone had no effect on Bcl-2 levels or phosphorylation (Fig. 6⇓ , compare Lanes 19 and 20). The combination of Taxol with the selective RAR agonists resulted in a down-regulation of Bcl-2 levels and an increase in its phosphorylation status (Fig. 6⇓ , Lanes 9–12 and Lanes 15–18). In contrast, the combination of Taxol with the RAR antagonist (BMS-313493) was only associated with an increase in the phosphorylation of Bcl-2 (Fig. 6⇓ , Lanes 21–24) without a change in protein expression levels. These results indicate that the synergistic effect of Taxol and RARα/β agonists may in part be attributable to the additive effects at the level of down-regulation and phosphorylation of bcl-2 that may result in the release of proapoptotic Bax activity, mitochondria membrane permeabilization, and the induction of apoptosis. These observations, together with the effects on AP1, may underlie the potent synergistic cytotoxic effect of these agents.

DISCUSSION

Natural and synthetic retinoids have shown their efficacy at inhibiting cell progression in a wide variety of tumor models. The data presented in this report reveal that RARα/β selective retinoids are sufficient to trigger inhibition of cell proliferation and enhance tumor cell sensitivity to cytotoxic agents. On a panel containing 18 tumor cell lines of various origin, the effect of RARα/β selective agonists at inhibiting cell growth are similar to that of ATRA, demonstrating that the RARγ or the pan RXR selectivity are not critically required for regulating tumor cell growth. These observations are of importance considering the severe mucocutaneous toxicity associated with the RARγ activity in pan retinoid ligands (41 , 42) , which have limited the therapeutic uses of these agents. It is possible that the weak sensitivity of many of the tumor cell lines used in this study to RAR-selective ligands is attributable to lower levels of expression of the retinoid receptors. However, recent reports have demonstrated that several lung cancer cell lines were resistant to the growth-inhibitory effects of ATRA, despite high levels of RXRs and the RARs, including RARβ (45 , 46) . This defect of the retinoids at inhibiting cell proliferation was attributed in part to a failure of the RARs at trans-repressing AP1 activity (45) . Furthermore, it has been suggested that the desensitization of lung cancer cells to RARβ-mediated growth inhibition is related to the balance of orphan receptors NUR-77 and COUP-TF, which governs RARβ promoter responsiveness to ATRA-activated RAR (46) . Taken together, this suggests that in addition to the retinoid receptor levels, the activity of the retinoids at inhibiting cell proliferation may also depend upon cross-regulation of the retinoid, AP1, COUP-TFs, and NUR77 signaling pathways.

Several reports have emphasized the cytotoxic effect of the RARγ-selective agonist, CD437, on a variety of tumor cell lines (47 , 48) . However, various lines of evidence suggest that the apoptotic pathway induced by CD437 is RAR independent (49, 50, 51) . Similarly, the genetic inactivation of the retinoid receptors in F9 embryonic carcinoma cells showed an RAR-independent apoptotic response of the cells to the retinoid analogue fenretinide (52) . Interestingly, DNA fragmentation or FACS measurements on a limited number of cell lines revealed that treatment of breast and ovarian cell lines for up to 6 days with the selective RAR pan-agonist (BMS-231974) or the α/β-selective agonists did not induce apoptosis (data not shown) but significantly inhibited the proliferation of these cells. Because the expression of the β-isotype of RAR is lost in most of the tumor cells, the RARα/β agonist activity is most likely mediated through the RARα isoform. Consistent with this hypothesis, a pure RARβ agonist (BMS-209641) had no effect on cell proliferation.3 However, it is conceivable that RARα might derepress RARβ expression through the RAR-specific response element located in RARβ2 promoter and induces a RARβ-mediated growth-inhibitory effect. However, of the cell lines examined in this study, only T47D displayed strong induction of RARβ in response to the selective retinoids. In contrast, two other cell lines, H3396 (breast) and HT3 (cervix), did not show any induction of RARβ expression in response to ATRA or the selective α/β agonists (data not shown). This observation is in agreement with the observations that the sensitivity of various murine melanoma cell lines to the growth-inhibitory effect of retinoids was not systematically associated with an induction of RARβ (43) . In contrast, the MCF7 clonogenic assays demonstrated the differentiating effect of the α/β selective retinoids. Taken together, these observations reveal that the growth-inhibitory activity of the α/β selective retinoids is not related to the induction of apoptosis and/or RARβ expression and suggest that the activity of these retinoids on cell proliferation might reflect an inhibition of cell cycle progression and/or induction of a pathway of differentiation.

The combination of the selective RARα/β agonists with various cytotoxic agents revealed an enhanced cytotoxicity to the tubulin-modifying agent, Taxol, and to a much lesser extent with vinblastine. In contrast, no significant effects were observed with DNA-damaging agents such as cisplatin, doxorubicin, or camptothecin. Wang et al. (32) recently reported that pretreatment with ATRA-sensitized breast cancer cells to Taxol. The lack of synergy between the RAR-selective retinoids and the DNA-damaging agents, cisplatin and doxorubicin, in contrast to other reports (30 , 31 , 53) , appears mostly related to the compound treatment schedules. It was shown that a pretreatment of breast cancer cells with ATRA is a prerequisite to the enhanced cell sensitization to cisplatin and doxorubicin (31 , 53) . Similar to our observations, ATRA had no beneficial effect on cisplatin or doxorubicin cell sensitivity in simultaneous treatment schedules (31) . The specific synergistic effect observed with the combination of Taxol and RARα/β agonists suggests that the combination effect of Taxol and retinoids is linked to the modulation of common signaling pathways. Indeed, we show that combination of RARα/β agonists and Taxol results in a down-regulation of Bcl-2 and an increase of its phosphorylation, a posttranslation modification shown to abrogate the antiapoptotic function of the protein (54) . It has been proposed that cells undergoing mitosis are predisposed to apoptosis to ensure the elimination of cells with aberrant chromosomal segregation (55) . This notion is consistent with our observations that the apoptosis resulting from the G2-M mitotic arrest and phosphorylation of Bcl-2 induced by Taxol is amplified by the retinoid-mediated down-regulation of Bcl-2 protein levels, which lowers the pool of Bcl-2 available to promote cell survival.

Retinoid ligands have also been shown to exert transrepression of AP1 activity (37 , 56) by disrupting c-Jun/c-Fos dimerization (57) . AP1 transcription factors can modulate proliferation, differentiation, or apoptosis, depending on the cell type. In fibroblasts and breast epithelial cells, AP1 activity is induced in response to multiple growth/mitogenic factors, resulting in the stimulation of cell proliferation, transformation, and tumoral progression (58 , 59) . We demonstrate here that the increase in AP1 activity observed in response to Taxol-induced JNK activity is dramatically inhibited in the presence of retinoids. These observations suggest that the enhanced activity of JNK induced by Taxol is uncoupled from the subsequent stimulation of AP1 activity in the presence of retinoids without affecting the capacity of Taxol at inducing Bcl-2 phosphorylation and cell apoptosis. Several reports have demonstrated that the effects of tubulin-modifying agents on both raf1/Bcl-2 (54 , 60) and MEKK1/JNKK/JNK (61, 62, 63) signaling pathways are linked and necessary for the induction of apoptosis. In particular, impairment of the JNK pathway induced by a dominant-inhibitory mutant has been shown to prevent phosphorylation of Bcl-2 and the ability of Taxol at regulating apoptosis (55 , 61) . Similarly, mutation of Bcl-2 phosphorylation sites was shown to abolish paclitaxel-induced apoptosis (64) . In agreement with our findings, Lee et al. (61) have shown that the combination of Taxol treatment with IκBα expression, which dissociates JNK activation from subsequent AP1 activity, had no impact on Taxol-induced apoptosis. These observations indicate that the combined effect of Taxol and retinoids enhance Taxol-induced JNK activity and compromise cell survival through retinoid inhibition of AP1 activity. Together these data support the synergistic inhibition of tumor cell proliferation obtained by the combination of Taxol with selective retinoids at the level of Bcl-2 and JNK/AP1, two key regulators of cell survival and proliferation.

The benefit of the use of retinoids in cancer was first demonstrated in patients afflicted with acute promyelocytic leukemia (15 , 16) . Subsequently, the combination of 13-cis-retinoic acid with paclitaxel or cisplatin and/or IFN-α has entered Phase I/II trials for the treatment of head and neck squamous cell carcinomas, non-small cell lung carcinomas, and prostate cancer (65 , 66) . Similarly, the pan-RAR agonist ALRT 1550, a potent inhibitor of AP1, has been included in a Phase I/II study on an heterogeneous population of 15 patients with advanced cancer, including non-small cell lung, thyroid, kidney, uterine leiomyosarcoma, prostate, and adenoid cystic carcinoma (67) . In this regard, the α,β selective retinoid ligands reported in this study may be useful in combination therapy with Taxol and offer the potential advantage of being devoid of adverse side effects such as mucocutaneous toxicity or chondrogenesis inhibition associated with RARγ activity.

Acknowledgments

We are grateful to Drs. H. Gronemeyer and P. Chambon for providing us with the MCF7-AP1 reporter cell line and for helpful discussion. We also thank Drs. A. Bianchi and F. Lee for providing cell lines and helpful discussion. We also acknowledge M-L. Wen and M. Arico for providing us with helpful advice on colony and tubulin assays, D. Hawkens for the RARβ expression analysis, and S. Roy and M. Belema for providing us with BMS-313493 and BMS-270394.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 To whom requests for reprints should be addressed, at Bristol-Myers Squibb, Pharmaceutical Research Institute, Oncology Drug Discovery, P. O. Box 4000, K19-04, Princeton, NJ 08543-4000. Phone: (609) 252-4313; Fax: (609) 252-6051; E-mail: valerie.vivat{at}bms.com

  • ↵2 The abbreviations used are: ATRA, all-trans retinoic acid; RAR, retinoic acid receptor; RXR retinoid X receptor; HDAC, histone deacetylase; JNK, c-Jun NH2-terminal kinase; AP, activator protein; PMA, phorbol 12-myristate 13-acetate; FBS, fetal bovine serum; tk, thymidine kinase.

  • ↵3 Unpublished observations.

  • Received May 1, 2001.
  • Accepted October 16, 2001.
  • ©2001 American Association for Cancer Research.

References

  1. ↵
    Blomhoff R. eds. . Vitamin A in Health and Disease, Institute for Nutrition Research, University of Oslo, : Marcel Dekker, New York Oslo, Norway 1994.
  2. ↵
    Love J. M., Gudas L. J. Vitamin A, differentiation and cancer. Curr. Opin. in Cell Biol., 6: 825-831, 1994.
    OpenUrlCrossRefPubMed
  3. ↵
    Lotan R. Retinoids in cancer chemoprevention. FASEB J., 10: 1031-1039, 1996.
    OpenUrlAbstract
  4. ↵
    Napoli J. L. Retinoic acid biosynthesis and metabolism. FASEB J., 10: 993-1001, 1996.
    OpenUrlAbstract
  5. ↵
    Hayden L. J., Hawk S. N., Sih T. R., Satre M. A. Metabolic conversion of retinol to retinoic acid mediates the biological responsiveness of human mammary epithelial cells to retinol. J. Cell. Physiol., 186: 437-447, 2001.
    OpenUrlCrossRefPubMed
  6. ↵
    Fitzgerald P., Teng M., Chandraratna R. A., Heyman R. A., Allegretto E. A. Retinoic acid receptor α expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res., 57: 2642-2650, 1997.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Zou C., Liebert M., Zou C., Grossman H. B., Lotan R. Identification of effective retinoids for inhibiting growth and inducing apoptosis in bladder cancer cells. J. Urol., 165: 986-992, 2001.
    OpenUrlCrossRefPubMed
  8. ↵
    Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J., 10: 940-954, 1996.
    OpenUrlAbstract
  9. ↵
    Gronemeyer H., Moras D. Nuclear receptors. How to finger DNA. Nature (Lond.), 375: 190-191, 1995.
    OpenUrlCrossRefPubMed
  10. ↵
    Forman B. M., Umesono K., Chen J., Evans R. M. Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell, 81: 541-550, 1995.
    OpenUrlCrossRefPubMed
  11. ↵
    Xu L., Glass C. K., Rosenfeld M. G. Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet. Dev., 9: 140-147, 1999.
    OpenUrlCrossRefPubMed
  12. ↵
    Hu X., Lazar M. A. Transcriptional repression by nuclear receptors. Trends Endocrinol. Metab., 11: 6-10, 2000.
    OpenUrlCrossRefPubMed
  13. ↵
    Robyr D., Wolffe A. P., Wahli W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol. Endocrinol., 14: 329-347, 2000.
    OpenUrlCrossRefPubMed
  14. ↵
    Renaud J. P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAR-γ ligand binding domain bound to all-trans retinoic acid. Nature (Lond.), 378: 681-689, 1995.
    OpenUrlCrossRefPubMed
  15. ↵
    Chomienne C., Fenaux P., Degos L. Retinoid differentiation therapy in acute promyelocytic leukemia. FASEB J., 10: 1025-1030, 1996.
    OpenUrlAbstract
  16. ↵
    Fenaux P., Chevret S., Guerci A., Fegueux N., Dombret H., Thomas X., Sanz M., Link H., Maloisel F., Gardin C., Bordessoul D., Stoppa A. M., Sadoun A., Muus P., Wandt H., Mineur P., Whittaker J. A., Fey M., Daniel M. T., Castaigne S., Degos L. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia (Baltimore), 14: 1371-1377, 2000.
    OpenUrlCrossRefPubMed
  17. ↵
    Widschwendter M., Berger J., Daxenbichler G., Muller-Holzner E., Widschwendter A., Mayr A., Marth C., Zeimet A. G. Loss of retinoic acid receptor β expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res., 57: 4158-4161, 1997.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Xu X. C., Sozzi G., Lee J. S., Lee J. J., Pastorino U., Pilotti S., Kurie J. M., Hong W. K., Lotan R. Suppression of retinoic acid receptor β in non-small-cell lung cancer in vivo: implication for lung cancer development. J. Natl. Cancer Inst., 89: 624-629, 1997.
    OpenUrlFREE Full Text
  19. ↵
    Khuri F. R., Lotan R., Kemp B. L., Lippman S. M., Wu H., Feng L., Lee J. J., Cooksley C. S., Parr B., Chang E., Walsh G. L., Lee J. S., Hong W. K., Xu X. C. Retinoic acid receptor β as a prognostic indicator in stage I non-small-cell lung cancer. J. Clin. Oncol., 18: 2798-2804, 2000.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Faria T. N., Mendelsohn C., Chambon P., Gudas L. J. The targeted disruption of both alleles of RARβ2 in F9 cells results in the loss of retinoic acid-associated growth arrest. J. Biol. Chem., 274: 26783-26788, 1999.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Sun S. Y., Wan H., Yue P., Hong W. K., Lotan R. Evidence that retinoic acid receptor β induction by retinoids is important for tumor cell growth inhibition. J. Biol. Chem., 275: 17149-17153, 2000.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Seewaldt V. L., Johnson B. S., Parker M. B., Collins S. J., Swisshelm K. Expression of retinoic acid receptor β mediates retinoic-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ., 6: 1077-1088, 1995.
    OpenUrlAbstract
  23. ↵
    Hayashi K., Yokozaki H., Naka K., Yasui W., Lotan R., Tahara E. Overexpression of retinoic acid receptor β induces growth arrest and apoptosis in oral cancer cell lines. Jpn. J. Cancer Res., 92: 42-50, 2001.
    OpenUrlCrossRefPubMed
  24. ↵
    Todesco A., Carli M., Iacona I., Frascella E., Ninfo V., Rosolen A. All-trans retinoic acid and interferon-α in the treatment of a patient with resistant metastatic osteosarcoma. Cancer (Phila.), 89: 2661-2666, 2000.
    OpenUrlCrossRefPubMed
  25. ↵
    Sun S. Y., Yue P., Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res., 60: 7149-7155, 2000.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Ferrara F. F., Fazi F., Bianchini A., Padula F., Gelmetti V., Minucci S., Mancini M., Pelicci P. G., Coco F. L., Nervi C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res., 61: 2-7, 2001.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Demary C., Wong L., Spanjaard R. A. Effect of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett., 163: 103-107, 2001.
    OpenUrlCrossRefPubMed
  28. ↵
    Pili R., Kruszewski M. P., Hager B. W., Lantz J., Carducci M. A. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res., 61: 1477-1485, 2001.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Shalinsky D. R., Bischoff E. D., Gregory M. L., Lamph W. W., Heyman R. A., Hayes J. S., Thomazy V., Davies P. J. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin. Cancer Res., 2: 511-520, 1996.
    OpenUrlAbstract
  30. ↵
    Caliaro M. J., Vitaux P., Lafon C., Lochon I., Nehme A., Valette A., Canal P., Bugat R., Jozan S. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br. J. Cancer, 75: 333-340, 1997.
    OpenUrlPubMed
  31. ↵
    Grunt T. W., Dittrich E., Offterdinger M., Schneider S. M., Dittrich C., Huber H. Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br. J. Cancer, 78: 79-87, 1998.
    OpenUrlPubMed
  32. ↵
    Wang Q., Yang W., Uytingco M. S., Christakos S., Wieder R. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res., 60: 2040-2048, 2000.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Sirchia S. M., Fregusson A. T., Sironi E., Subramanyan S., Orlandi R., Sukumar S., Sacchi N. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene, 19: 1556-1563, 2000.
    OpenUrlCrossRefPubMed
  34. ↵
    Garrigues J., Garrigues U., Hellstrom I., Hellstrom K. E. Ley specific antibody with potent anti-tumor activity is internalized and degradated in lysosomes. Am. J. Pathol., 142: 607-622, 1993.
    OpenUrlPubMed
  35. ↵
    Gehin M., Vivat V., Wurtz J. M., Losson R., Chambon P., Moras D., Gronemeyer H. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem. Biol., 6: 519-529, 1999.
    OpenUrlCrossRefPubMed
  36. ↵
    Lehmann J. M., Jong L., Fnajul A., Cameron J. M., Lu X. P., Haefner P., Dawson M. I., Pfahl M. Retinoids selective for retinoid X receptor α. Science (Wash. DC), 258: 1944-1946, 1992.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Chen J. Y., Penco S., Ostrowski J., Balaguer P., Pons M., Starrett J. E., Reczek P., Chambon P., Gronemeyer H. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J., 14: 1187-1197, 1995.
    OpenUrlPubMed
  38. ↵
    Sambrook J., Fritsch E. F., Maniatis T. . Molecular Cloning: A Laboratory Manual, Ed. 2 Cold Spring Harbor Laboratory Cold Spring Harbor, NY 1989.
  39. ↵
    Giannakakou P., Sackett D. L., Kang Y. K., Zhan Z., Buters J. T., Fojo T., Poruchynsky M. S. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulin that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem., 272: 17118-17125, 1997.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Coso O. A., Chiariello M., Yu J. C., Teramoto H., Crespo P., Xu N., Miki T., Gutkind J. S. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell, 81: 1137-1146, 1995.
    OpenUrlCrossRefPubMed
  41. ↵
    Standeven A. M., Teng M., Chandraratna R. A. S. Lack of involvement of retinoic acid receptor α in retinoid-induced skin irritation in hairless mice. Toxicol. Lett., 92: 231-240, 1997.
    OpenUrlCrossRefPubMed
  42. ↵
    Vuligonda V., Lin Y., Thacher S. M., Standeven A. M., Kochar D. M., Chandraratna R. A. S. A new class of RAR subtype selective retinoids: correlation of pharmacological effects with receptor activity. Bioorg. Med. Chem., 7: 263-270, 1999.
    OpenUrlCrossRefPubMed
  43. ↵
    Clifford J. L., Petrovich M., Chambon P., Lotan R. Modulation by retinoids of mRNA levels for nuclear retinoic acid receptors in murine melanoma cells. Mol. Endocrinol., 4: 1546-1555, 1990.
    OpenUrlCrossRefPubMed
  44. ↵
    Wang T. H., Wang H. S., Ichijo H., Giannakakou P., Foster J. S., Fojo T., Wimalasena J. Microtubule-interfering agents activate c-jun N-terminal kinase/stress-activated protein kinase through both ras and apoptosis signal-regulating kinase pathways. J. Biol. Chem., 273: 4928-4936, 1998.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Wan H., Hong W. K., Lotan R. Increased retinoic acid responsiveness in lung carcinoma cells that are nonresponsive despite the presence of endogenous retinoic acid receptor (RAR) β by expression of exogenous retinoid receptors retinoic X receptor α, RARα, and RARγ. Cancer Res., 61: 556-564, 2001.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Wu Q., Li Y., Liu R., Agadir A., Li M. O., Liu Y., Zhang X. K. Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization. EMBO J., 16: 1656-1669, 1997.
    OpenUrlAbstract
  47. ↵
    Li Y., Lin B., Agadir A., Liu R., Dawson M. I., Reed J. C., Fontana J. A., Bost F., Hobbs P. D., Zheng Y., Chen G. Q., Shroot B., Mercola D., Zhang X. K. Molecular determinant of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol. Cell. Biol., 18: 4719-4731, 1998.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    Sun S. Y., Yue P., Mao L., Dawson M. I., Shroot B., Lamph W. W., Heyman R. A., Chandraratna R. A., Shudo K., Hong W. K., Lotan R. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin. Cancer Res., 6: 1563-1573, 2000.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Marchetti P., Zamzami N., Joseph B., Schraen-Mashke S., Mereau-Richard C., Constantini P., Metivier D., Susin S. A., Kroemer G., Formstecher P. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res., 59: 6257-6266, 1999.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    Fontana J. A., Dawson M. I., Leid M., Rishi A. K., Zhang Y., Hsu C. A., Lu J. S., Peterson V. J., Jong L., Hobbs P. D., Chao W. R., Shroot B., Reichert U. Identification of a unique binding protein specific for a novel retinoid inducing cellular apoptosis. Int. J. Cancer, 86: 474-479, 2000.
    OpenUrlCrossRefPubMed
  51. ↵
    Hail N., Jr., Lotan R. Synthetic retinoid CD437 promotes rapid apoptosis in malignant human epidermal keratinocytes and G1 arrest in their normal counterparts. J. Cell. Physiol., 186: 24-34, 2001.
    OpenUrlCrossRefPubMed
  52. ↵
    Clifford J. L., Menter D. G., Wang M., Lotan R., Lippman S. M. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res., 59: 14-18, 1999.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    Toma S., Maselli G., Dastoli G., De Francisci E., Raffo P. Synergistic effect between doxorubicin and a low dose of all-trans-retinoic avid in MCF-7 breast cancer cell line. Cancer Lett., 116: 103-110, 1997.
    OpenUrlCrossRefPubMed
  54. ↵
    Blagosklonny M. V., Giannakakou P., El-Deiry W. S., Kingston D. G. I., Higgs P. I., Neckers L., Fojo T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res., 57: 130-135, 1997.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    Yamamoto K., Ichijo H., Korsmeyer S. J. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol. Cell Biol., 19: 8469-8478, 1999.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Pfahl M. Nuclear receptor/AP-1 interaction. Endocr. Rev., 14: 651-658, 1993.
    OpenUrlCrossRefPubMed
  57. ↵
    Zhou X. F., Shen X. Q., Shemshedini L. Ligand-activated retinoic acid receptors inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization. Mol. Endocrinol., 13: 276-285, 1999.
    OpenUrlCrossRefPubMed
  58. ↵
    Chen T. K., Smith L. M., Gebhardt D. K., Birrer M. J., Brown P. H. Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol. Carcinog., 15: 215-226, 1996.
    OpenUrlCrossRefPubMed
  59. ↵
    Yang L. M., Kim H. T., Munoz-Medellin D., Reddy P., Brown P. H. Induction of retinoid resistance in breast cancer cells by overexpression of cjun. Cancer Res., 57: 4652-4661, 1997.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Huang Y., Sheikh M. S., Fornace A. J., Jr., Holbrook N. J. Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Oncogene, 18: 3431-3439, 1999.
    OpenUrlCrossRefPubMed
  61. ↵
    Lee L. F., Li G., Templeton D. J., Ting J. P. Y. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-jun NH2-terminal kinase (JNK/SAPK). J. Biol. Chem., 273: 28253-28260, 1998.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    Stone A. A., Chambers T. C. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp. Cell Res., 254: 110-119, 2000.
    OpenUrlCrossRefPubMed
  63. ↵
    Yujiri T., Fanger G. R., Garrington T. P., Schlesinger T. K., Gibson S., Johnson G. L. MEK kinase 1 (MEKK1) transduces c-jun NH2-terminal kinase activation in response to changes in the microtubule cytoskeleton. J. Biol. Chem., 274: 12605-12610, 1999.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    Srivastava R. K., Mi Q. S., Hardwick J. M., Longo D. L. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci. USA, 96: 3775-3780, 1999.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    Gravis G., Pech-Goourgh F., Viens P., Alzieu C., Camerlo J., Oziel-Taieb S., Jausseran M., Maraninchi D. Phase II study of a combination of low dose cisplatin with 13-cis-retinoic acid and interferon-α in patients with advanced head and neck squamous cell carcinoma. Anticancer Drugs, 10: 369-374, 1999.
    OpenUrlPubMed
  66. ↵
    DiPaola R. S., Rafi M. M., Vyas V., Toppmeyer D., Rubin E., Patel J., Goodin S., Medina M., Medina P., Zamek R., Zhang C., White E., Gupta E., Hait W. N. Phase I clinical and pharmacological study of 13-cis-retinoic acid, interferon α, and paclitaxel in patients with prostate cancer and other advanced malignancies. J. Clin. Oncol., 17: 2213-2218, 1999.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    Soignet S. L., Miller V. A., Chen Y., Parker B. A., Amyotte S. A., Cato A. I. I., Matsumoto R. M., Warrell R. P. J. Phase 1–2 study of a retinoic acid receptor selective high affinity ligand (LGD1550). Proc. Annu. Meet. Am. Soc. Clin. Oncol., 17: A826 1998.
    OpenUrl
PreviousNext
Back to top
Cancer Research: 61 (24)
December 2001
Volume 61, Issue 24
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Synergistic Cytotoxicity Exhibited by Combination Treatment of Selective Retinoid Ligands with Taxol (Paclitaxel)
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Synergistic Cytotoxicity Exhibited by Combination Treatment of Selective Retinoid Ligands with Taxol (Paclitaxel)
Valerie Vivat-Hannah, Dan You, Cheryl Rizzo, Jean-Paul Daris, Philippe Lapointe, F. Christopher Zusi, Anne Marinier, Matthew V. Lorenzi and Marco M. Gottardis
Cancer Res December 15 2001 (61) (24) 8703-8711;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Synergistic Cytotoxicity Exhibited by Combination Treatment of Selective Retinoid Ligands with Taxol (Paclitaxel)
Valerie Vivat-Hannah, Dan You, Cheryl Rizzo, Jean-Paul Daris, Philippe Lapointe, F. Christopher Zusi, Anne Marinier, Matthew V. Lorenzi and Marco M. Gottardis
Cancer Res December 15 2001 (61) (24) 8703-8711;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Abstract LB-131: Profile of glucose metabolism in bladder cancer patients and the inhibitory effect of sulforaphane on bladder cancer glycolysis by regulating microRNA expression
  • Abstract 6470: Possibility of digital cytology of intraoperative ascites and lavage fluid in patients with colorectal cancer
  • Abstract 6471: Variable expression of ZEB-1, Bcl-2, and E-cadherin in human hepatocholangio and renal cell carcinomas
Show more Endocrinology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement